US-based Signant Health, an evidence generation company, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider, from Archimed.
Signant Health was formed in 2018 by the merger of CRF Health and Bracket to provide life science companies with patient-centric technology solutions that advance clinical research and transform the patient experience. The company’s integrated suite of applications combine advanced analytics and therapeutic area-specific scientific consulting, and are trusted by pharmaceutical companies of all sizes, including all of the top 20 pharmas, as well as CROs, biotechs, and academic institutions on over 4,000 global clinical trials. The company is backed by Genstar Capital.
Founded in 2004, Ametris is a global digital health solutions provider that transforms real-world patient data into validated clinical evidence based on proprietary algorithms and hundreds of corresponding publications. Its end-to-end platform combines advanced wearables, regulatory-aligned analytics and expert scientific support. It has supported more than 260 industry-sponsored trials across 150-plus countries and serves the top 25 pharmaceutical companies.
The transaction unifies Ametris’ wearable-derived digital outcome measures with Signant’s patient-reported outcomes, positioning Signant as a purpose-built, end-to-end clinical evidence platform for the pharmaceutical industry.
“This acquisition represents our commitment to advancing what’s possible in clinical evidence generation – building an end-to-end platform that integrates what patients say and what their bodies show,” said Roger Smith, CEO of Signant. “Together, we’re giving sponsors the tools to build stronger, more comprehensive efficacy cases.”
Archimed acquired ActiGraph in 2020 when the company was a hardware-led actigraphy specialist serving mostly academia and some pharma. Since then, it has been rebranded as Ametris and transformed it into a software-led, pharma-grade and pharma-focused digital endpoints leader.
“Joining Signant allows us to accelerate our vision of truly integrated multimodal evidence generation,” said Jeremy Wyatt, CEO of Ametris. “Our combined expertise creates a single partner committed to building purpose-designed integration. This benefits our customers through simplified vendor management today and seamless platform integration and converged workflows as our roadmap progresses.”
Press release: Signant Health Acquires Ametris to Create an End-to-End eCOA and Wearables Platform
